Why did Centene raise its 2025 revenue guidance but keep its EPS guidance unchanged?

The $6.0 billion revenue increase reflects higher expected premium from Marketplace enrollment outperformance ($5.0 billion) and Medicare Advantage annual enrollment gains ($1.0 billion). Because Marketplace and MA business operate at lower margins, the added revenue does not automatically translate into higher earnings. Management reaffirmed adjusted EPS guidance of greater than $7.25, suggesting the incremental volume is expected to carry commensurate medical cost and SG&A expense, and the company did not revise its margin assumptions.

What drove the increase in the health benefits ratio, and is it a concern?

The HBR rose to 87.5% from 87.1%, mainly due to Medicaid HBR climbing to 93.6% from 90.9%, attributed to influenza-like illnesses and acuity pressures that escalated in Q2 2024. This was partly offset by a Medicare HBR decline to 86.3% from 90.8% due to Inflation Reduction Act changes in Part D. Investors should monitor Medicaid cost trends, since the full-year HBR guidance of 88.9% to 89.5% implies continued elevated medical cost levels for the remainder of the year.

How strong is Centene's cash flow and liquidity position?

Operating cash flow was $1.5 billion in Q1 2025, compared with negative $456 million a year earlier, supported by net earnings and a $1.6 billion increase in medical claims liabilities. However, the quarter was partially held back by a delayed premium payment from a state partner, which was received in April 2025. Cash, investments and restricted deposits totaled $37.0 billion, and debt to capitalization improved to 39.5% from 40.0% a year earlier, though the company drew $750 million on its revolving credit facility.

What are the main growth drivers and new contract wins?

Growth was driven by Marketplace enrollment (up 29% year over year) and Medicare PDP membership (up 22%), reflecting strong product positioning and market growth. In April 2025, SilverSummit Healthplan was selected by Nevada to expand Medicaid managed care into rural areas and to run the state's Marketplace public option, with an expected start in January 2026 and a potential seven-year term. Meridian Health Plan of Illinois also secured a dual-eligible contract starting January 2026. These wins provide multi-year visibility but are subject to state approval.

What risks should investors consider from this report?

Key risks include dependence on enhanced advance premium tax credits for Marketplace growth, which the company flagged as subject to policy changes; Medicaid cost pressure, with a 93.6% HBR in that segment; and the lower-margin, fast-growing Marketplace business, which carries a higher SG&A ratio. The company also cited state payment timing delays and ongoing regulatory and policy uncertainty. Because the reported EPS beat was partly supported by the timing of working capital and a 24.7% effective tax rate, investors should weigh the sustainability of earnings momentum over the remaining quarters.

CNC 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 25, 2025. Cited figures are marked; the original filing is the authoritative source.

Centene Corporation (NYSE: CNC) reported first quarter 2025 results on April 25, 2025, with GAAP diluted EPS of $2.63^a and adjusted diluted EPS of $2.90, up 28% from $2.26 a year earlier.

Premium and service revenues rose 17% year over year to $42.5 billion^b, driven mainly by Commercial (+31%, largely Marketplace) and Medicare (+48%, largely PDP) growth. Total revenues were $46.6 billion. Membership expanded sharply in Marketplace (+29% to 5.6 million) and Medicare PDP (+22% to 7.9 million), while Traditional Medicaid membership declined and TRICARE eligibles dropped to zero following the Health Net Federal Services contract transition.

Profitability was mixed beneath the headline beat. The health benefits ratio rose to 87.5%^c from 87.1%, pressured by a higher Medicaid HBR (93.6% vs. 90.9%) tied to influenza-like illnesses and the escalation of acuity pressures, partly offset by a lower Medicare HBR (86.3% vs. 90.8%) reflecting Inflation Reduction Act Part D program changes. The SG&A ratio improved to 7.9% from 8.9% (adjusted 8.7% a year earlier), reflecting operating leverage and the mix benefit of PDP, though management noted Marketplace operates at a meaningfully higher SG&A ratio.

Operating cash flow was $1.5 billion^d, helped by a rise in medical claims liabilities, but was partly held back by a state premium payment delay later received in April. Management increased 2025 premium and service revenue guidance by $6.0 billion to $164.0–$166.0 billion, citing $5.0 billion of additional Marketplace premium and $1.0 billion from Medicare Advantage enrollment outperformance. Full-year adjusted diluted EPS guidance was reiterated at greater than $7.25, with GAAP diluted EPS guidance at greater than $6.19.

The company also highlighted new Nevada Medicaid and Marketplace contract awards and a Illinois dual-eligible contract, all expected to start in January 2026. The primary investor considerations are the sustainability of Marketplace growth given enhanced premium tax credit uncertainty, Medicaid cost pressure, and the reliance on guidance maintenance despite the revenue raise.

02—Key points

Key Highlights

Adjusted diluted EPS of $2.90 (up 28% YoY) beat the prior-year level of $2.26; GAAP diluted EPS was $2.63 versus $2.16 in Q1 2024.
Premium and service revenues grew 17% to $42.5 billion, led by Commercial (+31%) and Medicare (+48%), reflecting Marketplace and PDP growth.
Full-year 2025 premium and service revenue guidance raised by $6.0 billion to $164.0–$166.0 billion; adjusted diluted EPS guidance of greater than $7.25 reiterated.
Health benefits ratio increased to 87.5% from 87.1%, driven by a Medicaid HBR of 93.6% (up from 90.9%) amid influenza-like illness and acuity pressures, partly offset by Medicare improvement to 86.3%.
SG&A expense ratio improved to 7.9% from 8.9%, reflecting operating leverage and PDP mix, though Marketplace carries a higher SG&A ratio than the company average.
Total membership reached 27.9 million, with Marketplace up 29% to 5.6 million and Medicare PDP up 22% to 7.9 million, while Traditional Medicaid declined to 11.4 million.
Balance sheet remained solid with $37.0 billion in cash, investments and restricted deposits, total debt of $18.3 billion, and days in claims payable of 49 (down from 53 a year earlier, reflecting PDP mix).

03—Questions

Frequently Asked Questions

Why did Centene raise its 2025 revenue guidance but keep its EPS guidance unchanged?
The $6.0 billion revenue increase reflects higher expected premium from Marketplace enrollment outperformance ($5.0 billion) and Medicare Advantage annual enrollment gains ($1.0 billion). Because Marketplace and MA business operate at lower margins, the added revenue does not automatically translate into higher earnings. Management reaffirmed adjusted EPS guidance of greater than $7.25, suggesting the incremental volume is expected to carry commensurate medical cost and SG&A expense, and the company did not revise its margin assumptions.
What drove the increase in the health benefits ratio, and is it a concern?
The HBR rose to 87.5% from 87.1%, mainly due to Medicaid HBR climbing to 93.6% from 90.9%, attributed to influenza-like illnesses and acuity pressures that escalated in Q2 2024. This was partly offset by a Medicare HBR decline to 86.3% from 90.8% due to Inflation Reduction Act changes in Part D. Investors should monitor Medicaid cost trends, since the full-year HBR guidance of 88.9% to 89.5% implies continued elevated medical cost levels for the remainder of the year.
How strong is Centene's cash flow and liquidity position?
Operating cash flow was $1.5 billion in Q1 2025, compared with negative $456 million a year earlier, supported by net earnings and a $1.6 billion increase in medical claims liabilities. However, the quarter was partially held back by a delayed premium payment from a state partner, which was received in April 2025. Cash, investments and restricted deposits totaled $37.0 billion, and debt to capitalization improved to 39.5% from 40.0% a year earlier, though the company drew $750 million on its revolving credit facility.
What are the main growth drivers and new contract wins?
Growth was driven by Marketplace enrollment (up 29% year over year) and Medicare PDP membership (up 22%), reflecting strong product positioning and market growth. In April 2025, SilverSummit Healthplan was selected by Nevada to expand Medicaid managed care into rural areas and to run the state's Marketplace public option, with an expected start in January 2026 and a potential seven-year term. Meridian Health Plan of Illinois also secured a dual-eligible contract starting January 2026. These wins provide multi-year visibility but are subject to state approval.
What risks should investors consider from this report?
Key risks include dependence on enhanced advance premium tax credits for Marketplace growth, which the company flagged as subject to policy changes; Medicaid cost pressure, with a 93.6% HBR in that segment; and the lower-margin, fast-growing Marketplace business, which carries a higher SG&A ratio. The company also cited state payment timing delays and ongoing regulatory and policy uncertainty. Because the reported EPS beat was partly supported by the timing of working capital and a 24.7% effective tax rate, investors should weigh the sustainability of earnings momentum over the remaining quarters.

04—Continue

← View all 8-K filings